BioSpace News Archive

EW Healthcare Partners announced it raised over $745 million in EW Healthcare Partners Fund 2, L.P., the Firm’s second dedicated growth equity fund.

The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia’s intellectual property, and while they denied Lilly’s smaller counterclaim, ruled that Lilly is not liable for damages.

CStone Pharmaceuticals announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia’s Therapeutic Goods Administration has acknowledged the electronic Clinical Trial Notification the Company submitted for the trial.

Pfizer announced a $500 million investment in a state-of-the-art gene therapy manufacturing facility that is based on Dr. Samulski’s and AskBio’s AAV technology discoveries.

ACTO was named the winner of a Gold Stevie® Award in the Cloud Platform category in The 16th Annual International Business Awards®.

Ryan, a leading global tax services and software provider, announced that David Douglas has joined the Firm as Principal and Canadian Practice Leader of Scientific Research and Experimental Development (SR&ED).

The ACGME today released the CLER National Report of Findings 2019: Initial Visits to Sponsoring Institutions With 2 or Fewer Core Residency Programs.

Eon announced today the successful implementation and Go-Live of EonDirect at St. Peter’s Health in Helena, MT earlier this month

Veeva Systems (NYSE:VEEV) today announced that Joe Jimenez, former CEO of Novartis, and Rob Metcalf, vice president of medicines development at Eli Lilly and Company, are featured keynote speakers at the 2019 Veeva R&D Summit.

Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine.